Clinical trial
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus…
NCT00299819 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00299819 |
|---|---|
| Title | Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE) |
| Official title | A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lupus Erythematosus (SLE) |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lupus |
| Intervention type | Biological |
| Interventions | MEDI-545, MEDI 545 |
| Enrollment | 45 |
| Start date | Mar 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Mar 7, 2006 |
| Last update posted | Dec 18, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: